The firm will encounter stiff competition, particularly from BioMérieux and Luminex, but there are untapped opportunities for adoption, according to industry analysts.
The regulatory activity for the diagnostic platform follows ISO 13485:2003 certification in March. The firm is also planning a 510(k) submission to the FDA.
The company's net loss grew on higher expenses, while it said in its Form 10-Q that it plans to initiate a clinical trial for its microbiology diagnostic platform in H1 2015.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
